Cardiac Troponin Test (Troponin I & T)

Cardiac Troponin Test (Troponin I & T) — scientific infographic poster

Cardiac troponin (cTnI and cTnT) is the gold-standard biomarker for diagnosing acute myocardial infarction. Released from cardiomyocytes when the cell membrane is disrupted, it combines high sensitivity — it detects even minor myocardial injury — with high cardiac specificity, because the cardiac isoforms are structurally distinct from skeletal muscle troponin. The arrival of high-sensitivity troponin (hs-cTn) assays transformed the emergency evaluation of chest pain, making 0h/1h and 0h/2h rapid rule-in / rule-out algorithms possible where earlier assays needed six hours or more.

❤️ Interactive Visualization The Heart & Circulation — watch a blood cell make the loop Trace a blood cell through all four chambers and both circuits, with a live ECG, chamber pressures, and an exercise mode. Launch →

Table of Contents

  1. What the Cardiac Troponin Test Measures
  2. Biochemistry of the Troponin Complex
  3. Why Troponin Testing Is Ordered
  4. How the Test Is Performed
  5. Troponin I vs. Troponin T: Differences
  6. Reference Ranges and Result Interpretation
  7. The Troponin Rise-and-Fall Pattern
  8. Rapid Rule-In and Rule-Out Algorithms
  9. The HEART Score
  10. The Five Types of Myocardial Infarction
  11. Conditions That Elevate Troponin
  12. Non-Coronary Causes in Depth
  13. High-Sensitivity Troponin (hs-cTn)
  14. What Trials Report on Lowering Cardiac Risk
  15. Limitations of Troponin Testing
  16. Key Research Papers
  17. Connections
  18. Featured Videos

What the Cardiac Troponin Test Measures

Cardiac troponin is a protein complex found exclusively in heart muscle cells (cardiomyocytes). It plays a central role in regulating the contraction of the heart by controlling the interaction between actin and myosin, the two proteins that generate the mechanical force of heartbeat. The troponin complex has three subunits: troponin C (which binds calcium), troponin I (which inhibits contraction in the resting state), and troponin T (which anchors the complex to tropomyosin on the actin filament).

In a healthy heart, troponin remains inside cardiomyocytes. When heart muscle cells are damaged or die — as occurs during a myocardial infarction, myocarditis, or significant cardiac stress — the cell membranes break down and troponin leaks into the bloodstream. Because cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are structurally distinct from their skeletal muscle counterparts, laboratory assays can detect them with high cardiac specificity. Even small amounts of myocardial injury can produce a measurable rise in troponin.

Troponin testing has become the gold-standard biomarker for diagnosing acute myocardial infarction (heart attack) and for risk-stratifying patients presenting with chest pain. The advent of high-sensitivity troponin (hs-cTn) assays in the 2010s further transformed cardiac emergency medicine by measuring far lower concentrations: in the Dallas Heart Study, troponin T was detectable in 25.0% of adults aged 30 to 65 with a highly sensitive assay, against 0.7% with the standard assay (de Lemos 2010).

How Troponin Became the Standard

Troponin entered routine clinical use as a cardiac biomarker in the 1990s and rapidly displaced CK-MB (the MB isoform of creatine kinase), which had been the previous standard but was also present in skeletal muscle and therefore far less cardiac-specific. The 2000 ESC/ACC consensus document redefined myocardial infarction around the new marker: any troponin elevation above the 99th percentile of a healthy reference population, accompanied by a rise and/or fall pattern and evidence of ischemia. That document became the first "Universal Definition of Myocardial Infarction," and it has been revised three times since — in 2007, 2012, and 2018.

The two cardiac-specific isoforms measured in clinical practice are distinguished from their skeletal-muscle counterparts by structural features that the assay antibodies target directly:

Both are measured with highly specific monoclonal antibodies that do not cross-react with skeletal muscle isoforms under normal conditions — which makes the test cardiac-specific, not merely cardiac-sensitive. It is worth being precise about what that specificity does and does not buy: troponin identifies myocardial cell injury or death, but it does not identify the cause of that injury. Coronary atherosclerosis, cardiomyopathy, myocarditis, pulmonary embolism, and sepsis all produce the same signal. Sorting out which one is present relies on the clinical history, the ECG, echocardiography, and where appropriate coronary angiography.

Biochemistry of the Troponin Complex

The troponin complex is a trimeric regulatory protein embedded in the thin filament of striated muscle, sitting at the core of the calcium-regulated actin-myosin contraction cycle. Each of the three subunits has a distinct structural and functional role:

The Contraction Cycle

When intracellular calcium rises during an action potential, calcium binds TnC's regulatory site II. The resulting conformational change causes TnC to grab TnI's inhibitory domain, releasing TnI from actin. Tropomyosin then shifts and exposes the myosin-binding sites on actin, permitting cross-bridge cycling and contraction. When calcium is pumped back into the sarcoplasmic reticulum by SERCA, TnC releases its calcium, TnI rebinds actin, tropomyosin slides back over the myosin-binding sites, and the muscle relaxes.

Why Troponin Leaks in Two Phases

Ischemia that lasts long enough produces irreversible cardiomyocyte injury and disruption of the sarcolemmal membrane. Troponin then escapes from two pools, which Katus and colleagues described in 1991 as an unbound cytosolic pool and the structurally bound troponin of the myofibrils (Katus 1991, Am J Cardiol):

That slow second phase is diagnostically valuable: a patient who presents days after an episode of chest pain may still have measurable troponin from the original event, allowing a subacute MI to be identified retrospectively.

Why Troponin Testing Is Ordered

Cardiac troponin testing is ordered in a wide range of clinical situations:

How the Test Is Performed

Cardiac troponin is measured from a standard venous blood draw. No fasting is required. The sample is sent to the clinical laboratory immediately — troponin testing in emergency settings is typically processed as a STAT (urgent) order.

Because troponin rises progressively after cardiac injury rather than instantly, diagnosis rests on serial sampling. Rapid rule-in/rule-out protocols use one of these schedules:

Point-of-care (POC) troponin devices are also available for bedside testing in pre-hospital settings or resource-limited environments, though laboratory-based assays remain the gold standard for sensitivity and precision.

Troponin I vs. Troponin T: Differences

Both cardiac troponin I (cTnI) and cardiac troponin T (cTnT) are equally accepted as diagnostic markers for myocardial injury. They are structurally distinct proteins encoded by different genes, and their clinical performance characteristics differ slightly:

Cardiac Troponin I (cTnI):

Cardiac Troponin T (cTnT):

Both are internationally endorsed as the standard biomarkers for myocardial injury and MI diagnosis (Apple 2012); the practical differences show up mainly in skeletal muscle disease and kidney disease.

Reference Ranges and Result Interpretation

Troponin reference ranges are assay-specific and vary between laboratories. The universal diagnostic threshold for acute myocardial injury is the 99th percentile of a healthy reference population (also called the upper reference limit or URL). Any troponin elevation above the 99th percentile URL is considered abnormal and indicates myocardial injury.

Typical conventional troponin ranges (exact values differ by assay platform):

A note on the hs-cTnT numbers above. The 99th percentile of one assay depends on the reference population it is measured in. For hs-cTnT, three US population cohorts gave 99th percentiles of 18, 22 and 36 ng/L (the Dallas Heart Study, ARIC and the Cardiovascular Health Study, after excluding people with recent hospitalisation, overt cardiovascular disease or kidney disease), differences that paralleled the cohorts' ages (Gore 2014). A Swedish random population sample gave 24 ng/L (Hammarsten 2012). The limits that apply to any one result are therefore those of the laboratory and assay that produced it. The 99th percentile itself, despite arguments for higher cutoffs, is described in a 2020 review as remaining the best-established criterion for diagnosing acute MI (Sandoval 2020).

Results are read in clinical context:

Why the Reference Range Differs by Sex

Women consistently have lower 99th percentile troponin concentrations than men, for both hs-cTnT and hs-cTnI. Applying a sex-specific URL rather than one combined number does two things at once:

Finding more injury has not, so far, been shown to improve outcomes. In the High-STEACS stepped-wedge trial of 48,282 patients across 10 hospitals, sex-specific thresholds increased the identification of myocardial injury by 42% in women and 6% in men, but women with injury still received roughly half as many coronary treatments as men, and the one-year rate of reinfarction or cardiovascular death in women was not improved (Lee 2019).

Why the Reference Range Rises With Age

The 99th percentile climbs with age even among people considered healthy. In emergency-room patients without obvious conditions that raise troponin, the hs-cTnT 99th percentile was 12 ng/L under age 65 but 82 ng/L over 65 (Hammarsten 2012), and in the three US cohorts more than 10% of men aged 65 to 74 with no cardiovascular disease had values above the MI threshold (Gore 2014). In the Dallas Heart Study, detectable troponin T was linked to left ventricular hypertrophy, systolic dysfunction and kidney disease (de Lemos 2010), so the rise is not simply an artifact. For an older patient with a raised value, the rise-and-fall pattern across serial draws is what separates a stable personal baseline from an acute event.

The Rise/Fall (Delta) Criterion

A single value above the 99th percentile establishes myocardial injury. It does not establish acute myocardial infarction, which under the Fourth Universal Definition additionally requires a rising and/or falling pattern and evidence that ischaemia caused the injury. Delta criteria are assay-specific; the published examples for hs-cTnT include:

Back to Table of Contents

The Troponin Rise-and-Fall Pattern

The characteristic biokinetic pattern of troponin in acute MI is a rise-and-fall curve that reflects the release and gradual clearance of troponin from damaged cardiomyocytes. Understanding this pattern is essential for interpreting serial results:

A threshold plot of cardiac troponin against time since symptom onset, with the 99th-percentile upper reference limit drawn across it: in acute myocardial infarction troponin can appear within about 3 hours, can show an early peak at about 14 hours when the artery is reopened early, and stays raised for days — more than 130 hours in a 1991 study — so two serial draws show a change, while chronic injury sits above the same limit as a flat line whose serial draws do not move; the right-hand column states that one value above the limit means injury, a rise or fall means infarction, and in the TRAPID-AMI 0h/1h algorithm rule-in was met by either criterion alone. INJURY IS A LEVEL, INFARCTION IS A CHANGE cardiac troponin · time since symptom onset · the 99th-percentile upper reference limit from ~3 h early peak ~14 h still raised after 130 h 99th-percentile URL · assay-specific serial draws: no change chronic injury: stays flat serial draws: a rise acute MI an early draw may still read below the URL onset14 hday 1 130 hdays later time since symptom onset — hours, then days (axis compressed after 24 h) troponin → READ THE CHANGE, NOT THE LEVEL one value above the URL = myocardial injury the 99th percentile of a healthy reference population; sex-specific and assay-specific a rise and/or fall = acute infarction an evolving process needs a dynamic change across serial draws TRAPID-AMI 0h/1h rule-in: either one 0h hs-cTnT ≥ 52 ng/L, OR a 1-hour rise ≥ 5 ng/L one hs-cTnT assay; not transferable between assays a flat line above the URL is injury without an acute event — kidney disease, heart failure — and only serial draws tell the two apart. curve shape schematic, not to scale · timings from first-generation troponin T studies (Katus 1991)

The delta change (absolute or relative change between serial measurements) is the central diagnostic concept. The ESC algorithms set assay-specific delta cut-offs; for one hs-cTnT assay, the 0h/1h algorithm validated in TRAPID-AMI treated a 1-hour rise of at least 5 ng/L, or a 0h value of at least 52 ng/L, as a rule-in criterion (Mueller 2016).

Rapid Rule-In and Rule-Out Algorithms

The 2020 ESC guideline for acute coronary syndromes without persistent ST-segment elevation recommended the 0h/1h and 0h/2h high-sensitivity troponin algorithms as the first and second choices, ahead of the 0h/3h algorithm (as summarised by Chiang 2022). The 2023 ESC guideline for acute coronary syndromes sets out the ESC 0h/1h and 0h/2h rule-out and rule-in algorithms in its Figure 6, with cut-offs that are specific to each assay (Byrne 2023). These algorithms replaced the older practice of serial draws over six hours or more before a decision.

The 0h/1h Algorithm (Preferred)

Two hs-cTn measurements are taken: one at presentation and one exactly one hour later. Patients then fall into one of three zones. The figures below are for one hs-cTnT assay, as validated in the TRAPID-AMI multicenter study of 1,282 patients, 16.6% of whom had a final diagnosis of AMI (Mueller 2016):

The specific ng/L values are assay-dependent and are not transferable. The thresholds above apply to one hs-cTnT assay; each hs-cTnI assay has its own separately validated numbers, which the ESC guideline lists assay by assay, and applying one assay's cut-points to another assay's results is a recognised source of error.

The 0h/2h Algorithm

An alternative for departments where a precise one-hour re-draw is logistically difficult. Two samples are taken at presentation and two hours later. Rule-out requires a low presenting value with a small 2-hour change; rule-in requires a markedly elevated presenting value or a large 2-hour change, with assay-specific cut-offs. In a 2022 meta-analysis of 32 studies (30,066 patients), the 0h/2h algorithm had a pooled sensitivity of 98.6% and negative predictive value of 99.6% for ruling out AMI, against 99.1% and 99.8% for the 0h/1h algorithm (Chiang 2022).

The 0h/3h Algorithm

The older rapid algorithm, which uses the 99th percentile threshold plus a significant change across three hours. In the same meta-analysis it had a pooled sensitivity of 93.7% and negative predictive value of 98.7%, and its sensitivity was lower in studies that did not add clinical criteria (a GRACE score below 140 and being pain-free) than in studies that did (90.2% vs 98.4%). The authors concluded that the 0h/1h and 0h/2h algorithms have higher sensitivities and negative predictive values than the 0h/3h algorithm (Chiang 2022).

Back to Table of Contents

The HEART Score

Troponin is one input, not the whole decision. The HEART score is a validated five-component clinical decision tool — History, ECG, Age, Risk factors, Troponin — that scores each element 0, 1, or 2 for a total of 0 to 10. In its prospective validation in 2,440 patients at ten Dutch hospitals, the rate of major adverse cardiac events (MACE) within six weeks fell into three bands (Backus 2013):

The HEART score's c-statistic (0.83) was significantly higher than those of the TIMI (0.75) and GRACE (0.70) scores. The authors wrote that low scores excluded short-term MACE with more than 98% certainty, so that "reserved policies" might be considered, while high scores might indicate "more aggressive policies" (Backus 2013).

The Five Types of Myocardial Infarction

The Fourth Universal Definition of Myocardial Infarction classifies MI into five types by pathophysiology, not by troponin magnitude. Two patients can have identical troponin values and very different underlying problems, so the classification shapes how each is managed.

Type 1 — Atherosclerotic Plaque Event

Spontaneous MI caused by atherosclerotic plaque rupture, erosion, or fissuring with intraluminal thrombus formation, leading to acute coronary occlusion or sharply reduced coronary flow. This is the classic heart attack, presenting as either STEMI or NSTEMI. Guideline management covers revascularization and antithrombotic and secondary-prevention drug therapy (Byrne 2023).

Type 2 — Supply-Demand Mismatch

Myocardial injury caused by something other than plaque disruption, in which oxygen demand outstrips supply. Troponin rises and falls as it does in Type 1, but coronary angiography reveals no culprit lesion. Common triggers include:

Management of Type 2 MI centers on the underlying condition. Evidence for antiplatelet and anticoagulant therapy in Type 2 MI is much more limited than in Type 1, and these drugs carry bleeding risk — a particular concern in a bleeding or septic patient.

Types 3, 4, and 5

The higher multiples required for Types 4a and 5 exist because both procedures cause some myocardial injury by design; the threshold has to clear that expected background before a procedural infarction can be called.

Back to Table of Contents

Conditions That Elevate Troponin

While troponin elevation is most strongly associated with acute MI, it can also be elevated in a broad range of other conditions. These alternatives — type 2 MI and non-ischaemic myocardial injury — are part of the differential for a positive result:

Primary cardiac causes:

Non-cardiac causes (secondary myocardial injury):

Back to Table of Contents

Non-Coronary Causes in Depth

Any condition that injures cardiomyocytes will raise troponin, whether or not a coronary artery is involved. The list above is the quick reference; what follows is the detail that matters when a troponin comes back positive and the coronary arteries turn out to be clean.

Myocarditis

Inflammation of the myocardium arising from viral infection (coxsackievirus B, adenovirus, parvovirus B19, influenza, SARS-CoV-2), autoimmune processes (giant cell myocarditis, eosinophilic myocarditis), or toxic exposures (anthracyclines, immune checkpoint inhibitors). Troponin can be markedly elevated, and the ECG may show diffuse ST elevation that mimics a STEMI closely enough to send a patient to the catheterization laboratory. The angiogram shows normal or non-obstructive arteries. Cardiac MRI with late gadolinium enhancement is the key diagnostic tool, showing a patchy, often subepicardial pattern that does not follow a coronary territory.

Pulmonary Embolism

Acute massive or submassive pulmonary embolism causes abrupt right ventricular pressure overload. The RV free wall, which is normally perfused at low pressure and has little reserve, sustains subendocardial ischemia when intracavitary pressure rises suddenly. A meta-analysis of 20 studies (1,985 patients) found that 19.7% of patients with raised troponin died in the short term, against 3.7% of those with normal troponin (odds ratio 5.24), and the association held in hemodynamically stable patients (odds ratio 5.90) and for both troponin I and T (Becattini 2007). Troponin is therefore used, alongside clinical scores and imaging of the right ventricle, in grading the severity of a pulmonary embolism.

Acute Decompensated Heart Failure

Both acute and chronic heart failure are associated with troponin elevation. During acute decompensation, cardiomyocyte injury comes from several directions at once: a raised left ventricular end-diastolic pressure compresses subendocardial perfusion, catecholamine excess drives demand up, and neurohormonal activation adds further stress. In 5,284 patients with chronic heart failure from the Val-HeFT and GISSI-HF trials, increases in hs-cTnT over three to four months were associated with all-cause mortality (hazard ratios 1.59 and 1.88) after adjustment for risk factors and for baseline hs-cTnT and NT-proBNP, although the change added only modest prognostic discrimination beyond the baseline value, and only for fatal outcomes (Masson 2012).

Takotsubo (Stress) Cardiomyopathy

Also called apical ballooning syndrome or broken heart syndrome. A massive catecholamine surge — emotional shock, severe physical stress, the post-surgical state — produces a transient wall-motion abnormality with ballooning of the left ventricular apex and preserved or hyperdynamic basal contraction, giving the characteristic "octopus pot" shape on ventriculography that named the syndrome. Troponin rises, though usually to a lower peak than an equivalent-territory STEMI would produce, and the disproportion between a modest troponin and a large wall-motion abnormality is itself a diagnostic clue. Coronary angiography shows no obstructive disease, and ejection fraction typically recovers.

Sepsis-Induced Cardiomyopathy

Direct cardiomyocyte injury from circulating cytokines (TNF-alpha, IL-1beta, IL-6), endotoxin, reactive oxygen species, and nitric oxide produces a reversible myocardial depression in some septic patients. In a meta-analysis of 13 studies (1,227 patients), troponin was elevated in 61%, and elevation was associated with all-cause mortality (relative risk 1.91), including after adjustment for prognostic scores in four studies (odds ratio 1.92); the authors note that the precise role of troponin and its optimal cut-offs in sepsis are still undefined (Bessière 2013).

Chronic Kidney Disease and Dialysis

Both cTnI and cTnT run chronically elevated in chronic kidney disease. The cause is a combination of reduced clearance, uremia-mediated cardiomyocyte injury, left ventricular hypertrophy, and a genuinely high prevalence of subclinical coronary disease — it is not simply a laboratory artifact, and the elevation carries real prognostic weight. The Fourth Universal Definition notes that hs-cTnT is more often elevated than hs-cTnI in this population. In dialysis patients a single number says little on its own; serial measurement is used to look for a dynamic change against the patient's own elevated baseline.

Skeletal Muscle Disease and Rhabdomyolysis

This is the one situation where the choice of assay changes the answer, and it is easy to get backwards. Diseased skeletal muscle can contain a protein that cTnT assays detect, producing an elevated cTnT without cardiac injury. In the Mayo Clinic series that documented this, 16 patients with myopathies had increased cTnT but not cTnI, and biopsies of their diseased muscle reacted with the cTnT assays' antibodies; the authors proposed re-expressed isoforms as the source (Jaffe 2011). Measuring cTnI was how that study separated the two.

Strenuous Endurance Exercise

Troponin can rise after prolonged hard exercise in people with no known heart disease. A meta-analysis of 26 studies (1,120 cases) found post-exercise troponin T above the assay's detection limit in 47% of participants; detection after cycling events was about half that after running events (27% vs 52%), and heavier individuals in shorter endurance events, primarily marathon runners, were slightly more likely to show it (Shave 2007).

Other Causes

Back to Table of Contents

High-Sensitivity Troponin (hs-cTn)

High-sensitivity cardiac troponin (hs-cTn) assays represent a major technological advance over conventional troponin assays. The key differences:

The adoption of hs-cTn has increased the diagnosis of MI, particularly in women (Shah 2015), while the rapid algorithms allow many patients with chest pain to be ruled out sooner than with extended observation (Mueller 2016; Chiang 2022).

What Officially Makes an Assay "High-Sensitivity"

The generation of a troponin assay is not defined by a particular technology but by two analytical performance criteria discussed by the International Federation of Clinical Chemistry (IFCC) task force (Apple 2012):

The imprecision criterion matters as much as the detection criterion. An assay that can technically report very low numbers but scatters them widely from run to run cannot support a rule-out decision built on a 1-hour change of less than 3 ng/L; the whole 0h/1h approach depends on the assay being able to distinguish a small real change from its own noise. The second criterion produces the conceptual shift: because troponin is now measurable at physiological background levels in nearly everyone, clinicians can track a dynamic change from an individual's own baseline instead of waiting for a threshold to be crossed from "undetectable."

Major Validated Platforms

Before high-sensitivity assays, confirming a rise commonly took serial draws on admission and at 3 and 6 hours (as in Keller 2009). In TRAPID-AMI, the 0h/1h algorithm assigned 63.4% of patients to rule-out after the one-hour sample (Mueller 2016). The corresponding hazard is that assay thresholds are not interchangeable: a hospital switching platforms needs a new set of cut-points, and published guidance exists specifically for institutions making that transition.

Back to Table of Contents

What Trials Report on Lowering Cardiac Risk

For people who have had a troponin-positive event or who are at elevated cardiovascular risk, this is what the research reports on lifestyle, nutrition and medicines. Decisions about treatment belong with a clinician.

Lifestyle Foundations

Nutrition Research

Medical Management After AMI

For patients who have had a confirmed MI with troponin elevation, guideline-directed medical therapy typically includes dual antiplatelet therapy, high-intensity statin therapy, ACE inhibitors or ARBs (especially with reduced ejection fraction), beta-blockers (in the acute setting and for reduced ejection fraction), and aldosterone antagonists when indicated. These medications have robust evidence for reducing recurrent MI, heart failure, and death.

Limitations of Troponin Testing

Back to Table of Contents

Key Research Papers

Every citation below was checked against the PubMed record (most recently on 14 October 2026); the title, journal, volume, and pages match the linked PMID.

Guidelines and Definitions

  1. Thygesen K, Alpert JS, Jaffe AS, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72(18):2231–2264. — PubMed PMID: 30153967
  2. Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. — PubMed PMID: 32860058
  3. Januzzi JL Jr, Mahler SA, Christenson RH, et al. Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019;73(9):1059–1077. — PubMed PMID: 30798981
  4. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–3826. — PubMed PMID: 37622654

Rapid Rule-Out Algorithms and Early Diagnosis

  1. Mueller C, Giannitsis E, Christ M, et al. Multicenter Evaluation of a 0-Hour/1-Hour Algorithm in the Diagnosis of Myocardial Infarction With High-Sensitivity Cardiac Troponin T (TRAPID-AMI). Ann Emerg Med. 2016;68(1):76–87. — PubMed PMID: 26794254
  2. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361(9):858–867. — PubMed PMID: 19710484
  3. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009;361(9):868–877. — PubMed PMID: 19710485
  4. Body R, Carley S, McDowell G, et al. Rapid exclusion of acute myocardial infarction in patients with undetectable troponin using a high-sensitivity assay. J Am Coll Cardiol. 2011;58(13):1332–1339. — PubMed PMID: 21920261
  5. Shah AS, Anand A, Sandoval Y, et al. High-sensitivity cardiac troponin I at presentation in patients with suspected acute coronary syndrome: a cohort study. Lancet. 2015;386(10012):2481–2488. — PubMed PMID: 26454362
  6. Backus BE, Six AJ, Kelder JC, et al. A prospective validation of the HEART score for chest pain patients at the emergency department. Int J Cardiol. 2013;168(3):2153–2158. — PubMed PMID: 23465250
  7. Chiang CH, Chiang CH, Pickering JW, et al. Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction: An International Collaborative Meta-analysis. Ann Intern Med. 2022;175(1):101–113. — PubMed PMID: 34807719
  8. Pickering JW, Than MP, Cullen L, et al. Rapid Rule-out of Acute Myocardial Infarction With a Single High-Sensitivity Cardiac Troponin T Measurement Below the Limit of Detection: A Collaborative Meta-analysis. Ann Intern Med. 2017;166(10):715–724. — PubMed PMID: 28418520

Assay Characteristics and Reference Limits

  1. Apple FS, Collinson PO; IFCC Task Force on Clinical Applications of Cardiac Biomarkers. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem. 2012;58(1):54–61. — PubMed PMID: 21965555
  2. Giannitsis E, Kurz K, Hallermayer K, et al. Analytical validation of a high-sensitivity cardiac troponin T assay. Clin Chem. 2010;56(2):254–261. — PubMed PMID: 19959623
  3. Sandoval Y, Apple FS, Saenger AK, et al. 99th Percentile Upper-Reference Limit of Cardiac Troponin and the Diagnosis of Acute Myocardial Infarction. Clin Chem. 2020;66(9):1167–1180. — PubMed PMID: 32871000
  4. Hammarsten O, Fu ML, Sigurjonsdottir R, et al. Troponin T percentiles from a random population sample, emergency room patients and patients with myocardial infarction. Clin Chem. 2012;58(3):628–637. — PubMed PMID: 22258764
  5. Gore MO, Seliger SL, Defilippi CR, et al. Age- and sex-dependent upper reference limits for the high-sensitivity cardiac troponin T assay. J Am Coll Cardiol. 2014;63(14):1441–1448. — PubMed PMID: 24530665
  6. Shah AS, Griffiths M, Lee KK, et al. High sensitivity cardiac troponin and the under-diagnosis of myocardial infarction in women: prospective cohort study. BMJ. 2015;350:g7873. — PubMed PMID: 25609052
  7. Lee KK, Ferry AV, Anand A, et al. Sex-Specific Thresholds of High-Sensitivity Troponin in Patients With Suspected Acute Coronary Syndrome. J Am Coll Cardiol. 2019;74(16):2032–2043. — PubMed PMID: 31623760
  8. Katus HA, Remppis A, Neumann FJ, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation. 1991;83(3):902–912. — PubMed PMID: 1999039
  9. Katus HA, Remppis A, Scheffold T, et al. Intracellular compartmentation of cardiac troponin T and its release kinetics in patients with reperfused and nonreperfused myocardial infarction. Am J Cardiol. 1991;67(16):1360–1367. — PubMed PMID: 1904190

Troponin Beyond Acute MI

  1. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304(22):2503–2512. — PubMed PMID: 21139111
  2. Masson S, Anand I, Favero C, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation. 2012;125(2):280–288. — PubMed PMID: 22139751
  3. Jaffe AS, Vasile VC, Milone M, et al. Diseased skeletal muscle: a noncardiac source of increased circulating concentrations of cardiac troponin T. J Am Coll Cardiol. 2011;58(17):1819–1824. — PubMed PMID: 21962825
  4. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation. 2007;116(4):427–433. — PubMed PMID: 17606843
  5. Bessière F, Khenifer S, Dubourg J, et al. Prognostic value of troponins in sepsis: a meta-analysis. Intensive Care Med. 2013;39(7):1181–1189. — PubMed PMID: 23595497
  6. Shave R, George KP, Atkinson G, et al. Exercise-induced cardiac troponin T release: a meta-analysis. Med Sci Sports Exerc. 2007;39(12):2099–2106. — PubMed PMID: 18046180
  7. Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018;71(16):1755–1764. — PubMed PMID: 29567210
  8. Lai JSY, Yeong N, Tan XY, et al. When troponin results lie: A narrative review and practical approach to spurious hypertroponinemia. Am J Med. 2026;139(5):626–633. — PubMed PMID: 41519456

Risk Reduction After a Troponin-Positive Event

  1. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (REDUCE-IT). N Engl J Med. 2019;380(1):11–22. — PubMed PMID: 30415628
  2. Estruch R, Ros E, Salas-Salvadó J, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts (PREDIMED). N Engl J Med. 2018;378(25):e34. — PubMed PMID: 29897866 (the corrected and republished report; it replaces the withdrawn 2013 N Engl J Med paper, which this page does not rely on)

PubMed Topic Searches

  1. PubMed: High-sensitivity troponin and acute MI diagnosis
  2. PubMed: 0h/1h troponin rule-out protocol (ESC guidelines)
  3. PubMed: Troponin rapid rule-out algorithm in the emergency department
  4. PubMed: Cardiac troponin I vs. T in acute coronary syndrome
  5. PubMed: Non-cardiac causes of troponin elevation
  6. PubMed: Type 2 myocardial infarction and supply-demand mismatch
  7. PubMed: Sex-specific troponin thresholds and women's MI diagnosis
  8. PubMed: Troponin elevation in chronic kidney disease
  9. PubMed: Hs-cTn as a community cardiovascular risk biomarker
  10. PubMed: Troponin in myocarditis diagnosis and prognosis
  11. PubMed: Fourth Universal Definition of MI and troponin
  12. PubMed: HEART score and chest pain risk stratification

External Authoritative Resources

  1. MedlinePlus — Laboratory Tests Reference
  2. MedlinePlus — Medical Tests (U.S. National Library of Medicine)
  3. StatPearls / NCBI Bookshelf — Cardiac Troponin
  4. U.S. FDA — Biotin Interference with Troponin Lab Tests: Assays Subject to Biotin Interference

Back to Table of Contents

Connections

Back to Table of Contents